We have characterized N-13 ammonia as a myocardial blood flow imaging agent suitable for positron-emission computed tomography. However, the mechanisms of uptake and retention of this agent in myocardium are not known, and effects of altered metabolism were not considered. Therefore, we studied the uptake and retention of N-13 ammonia in myocardium under various hemodynamic and metabolic conditions in open-chest dogs. N-13 ammonia was extracted nearly 100% during its initial capillary transit, followed by metabolic trapping that competed with flow-dependent back diffusion. At control flows, the first capillary transit extraction fraction (E) of N-13 ammonia averaged 0.82 ± 0.06. It fell with higher flows by E = 1 -0.607 exp -125/F. Myocardial N-13 tissue clearance half-times were similarly inversely related to blood flow, and ranged from 110-642 minutes. Cardiac work and changes in the myocardial inotropic state induced by isoproterenol and propranolol did not affect E or the tissue clearance half-times. Low plasma pH reduced E by an average of 20%, while elevated plasma pH had no effect. Decreases in flow below control also were associated with a fall in E. Inhibition of glutamine synthetase with L-methionine sulfoximine impaired metabolic trapping of N-13 ammonia and implicates the glutamic acid-glutamine reaction as the primary mechanism for ammonia fixation. The product of E times flow predicts the myocardial N-13 tissue concentrations, which increased by 70% when flow was doubled. Thus, blood flow and metabolic trapping are the primary determinants of myocardial uptake and retention of N-13 ammonia. The relative constancy of metabolic trapping over a wide range of hemodynamic and metabolic conditions demonstrates the value of N-13 ammonia as a myocardial blood flow imaging agent.
N-13 AMMONIA* has been characterized as an indicator for the noninvasive visualization of regional myocardial perfusion by positron computed tomography (PCT).' Use of N-13 ammonia has also permitted noninvasive detection of mild, 47% diameter coronary stenosis in the intact dog. 2 Because fixation of N-13 ammonia in myocardium occurs through metabolic pathways, alterations in both the hemodynamic and metabolic state of the heart could modify the uptake of N-13 ammonia, and hence, limit its value as a flow indicator. In blood, N-13 (NH3) ammonia exists primarily in its ionic species, NH4+, the ammonium ion, which apparently can substitute for K+ on the sodium-potassium transmembraneous exchange system in red blood cells.3 It thus may be actively transported into myocardium. On the other hand, NH3 can diffuse across cell membranes because of its lipid solubility and is rapidly replenished by conversion of NH4+ to NH3 as it leaves the vascular space.4" 5Transmembrane exchange therefore may occur through an active transport mechanism or *The term ammonia is used to refer to the chemical equilibrium of NH3 NH4+ in which the prominent form is NH4+. by diffusion. Studies by Kobayashi6 in the dog and by Davidson and Sonnenblick7 in the isolated perfused rat heart suggest that the transmembraneous exchange of ammonia is influenced by the concentration gradient across the cell membrane.
Removal from or metabolic fixation of ammonia within skeletal muscle and myocardium may occur in several ways8: diffusion out of the cell; amination of ketoacids, e.g., a-ketoglutarate to glutamic acid; amidation of glutamic acid to glutamine; and formation of carbamoyl phosphate as a substrate for synthesis of amino acids and urea. As is the case in the brain, 9 10 the glutamic acid-glutamine pathway appears to be the predominant route of removal of ammonia in myocardium. 6-8, 11, 12 This reaction requires ATP and is mediated by the enzyme glutamine synthetase. Smirnov et al. 13 demonstrated formation of urea in human and canine myocardium. Thus, glutamine and, to a lesser extent, urea serve as means for ammonia transport from the myocardium to the kidney for excretion.
Ammonia removal and production are linked to carbohydrate metabolism (e.g., amination of ketoacids and deamination of amino acids" and modulation of phosphofructokinase activity),14 and hence, to pathways important for production of high-energy phosphates. Endogenous ammonia is derived through catabolism of cardiac proteins8 and probably through deamination of AMP in the adenylic acid cycle as demonstrated in both skeletal'3' 16 and cardiac muscle."7 This latter mechanism may account for the increase in myocardial ammonia concentrations during high work load, ischemia and hypoxia in dogs and rats6, 7, 12 The relationship between ammonia fixation and cardiac metabolism suggests that uptake, retention and clearance of exogenous ammonia, e.g., i.v. N-13 ammonia, may be modified by alterations in the metabolic state of the heart in several ways: competition between exogenous and endogenous ammonia for substrates involved in its fixation; depletion of substrates important for removal of intracellular ammonia; inhibition of activation of enzymes mediating these pathways; and changes in the transmembrane gradient of ammonia, e.g., elevated intracellular ammonia concentrations during high cardiac work. In this study we examined the myocardial uptake, retention and clearance of N-13 ammonia in relation to myocardial blood flow at different states of cardiac work and metabolism, during alterations in plasma glucose and plasma pH levels and during ischemia in order to determine to what extent the extraction and retention of N-13 ammonia is dependent upon metabolism, and to define more clearly the value and limitations of N-13 ammonia for myocardial perfusion imaging.
Materials and Methods

Animal Instrumentation
Forty-three mongrel dogs weighing from 18.5-35.5 kg (mean 25.5 kg) were studied after an overnight fast. Each dog was anesthetized with sodium pentobarbital (25 mg/kg) and ventilated with room air. After a left thoracotomy, the pericardium was incised widely and sutured to the chest wall to form a cradle in which the heart was suspended. An electromagnetic flow probe (Series 500, Biotronix) was fitted snugly around the proximal left circumflex coronary artery. Mechanical zero flow was established during transient coronary occlusion with a snare placed distally to the flow probe. For intracoronary injection of N-13 ammonia and vasodilatators, a 30-gauge needle connected to a fine plastic tubing (Lymphangiography set no. 6677, Becton-Dickinson) was inserted into the left circumflex coronary artery. Radioactive microspheres for measurements of myocardial blood flow were injected into the left atrium through a small polyethylene tube. Systemic blood pressure was monitored through a catheter positioned in the aorta and connected to a Statham P23Db pressure transducer. A second catheter advanced through the femoral artery into the aorta was used for withdrawal of arterial blood samples. All hemodynamic measurements were continuously monitored on an eight-channel directwriting physiologic recorder .
To determine the retention of N-13 ammonia in myocardium and its subsequent clearance, a shielded and collimated 7.5 X 5.0-cm NaI(Tl) scintillation detector was positioned over the heart so that the field of detection encompassed the myocardium supplied by the left circumflex coronary artery but excluded the site of N-13 ammonia administration. Data were collected in 0.1-second increments and stored in a digital computer (Scintigraphic Data Analyzer 5407, Hewlett-Packard).
Determination of the Extraction Fraction of N-13 Ammonia N-13 ammonia (20-40 uCi contained in 0.2 ml of saline) was preloaded into the left circumflex coronary artery cannula and then rapidly flushed (< 1 second) with 1 ml of normal saline into the left circumflex coronary artery. The myocardial activity was recorded for 20 minutes. The time-activity curve, corrected for physical decay, was plotted on semilogarithmic paper and the numerical values were printed out at 0. 10MN MINUTES FIGURE 1. Myocardial time-activity curve obtained after intracoronary injection of N-13 ammonia and correctedfor physical decay. At the time ofstudy, myocardial bloodflow (MBF) was 187 ml/min/100 g. The 2-second peak-activity phase A represents the initial indicator transit through the vascular and extravascular space. All of the injected N-13 activity is in the field of the NaI detector and the recorded counts are proportional to the total activity injected. During the early phase B, a fraction of N-13 ammonia diffuses back into the vascular space and leaves the myocardium. The slow monoexponential phase C represents the residualfunction or the fraction of N-13 ammonia that is retained in myocardium. The single-pass extraction fraction (E) is determined by extrapolating the residue fraction C back to the time of injection (peak activity A) and from the ratio R'/A. T, = half-time. The peak activity (phase A) is proportional to the total amount of N-13 ammonia injected and its 2-3-second plateau represents its transit through the vascular and extravascular space. The activity subsequently falls rapidly (phase B) to a slow, monoexponential phase C (residue function) that is proportional to the amount of N-13 activity retained in myocardium. The singlepass extraction fraction (E) was determined by extrapolating the slope of the residue function C back to the time of peak activity and dividing the value at the intercept R' by the peak activity A. The values obtained for E were always related to the flow at the time of the bolus administration of N-13 ammonia, which frequently caused a transient, less-than-10% increase in flow not more than 5-7 seconds long. The myocardial half-times were calculated from the slopes of phases C and B (for phase B after the contribution of phase C had been peeled off). This method has been used and validated for studies in the heart'8 19 and the brain.5 20
Experimental Protocol
The E of N-13 ammonia was determined three to five times. To allow for physical decay of the shortlived N-13 (10-minute half-life) to negligible levels, individual experimental runs were performed at 1-hour intervals. At least one measurement in each dog was obtained in the control state.
Effects of Myocardial Blood Flow
To determine the relationship of myocardial blood flow and the kinetics of N-13 ammonia in myocardium, flow in the left circumflex coronary artery was either reduced by partial constriction with a mechanical screw-type occluder or increased by continuous intracoronary infusion of papaverine at rates of 0.4-1.0 mg/min. At maximum infusion rates, left circumflex flow was usually four to five times above control. In instances of tachycardias (150-170 beats/min), and thus relatively high control flows, heart rates were reduced by i.v. xylazine (Rompun; Haver-Lockhart Lab), 0.10-0.25 mg/kg, a parasympathomimetic general anesthetic agent.
Effects of Myocardial Inotropic State
The myocardial inotropic state, and hence, the metabolic state, was either enhanced by i.v. isoproterenol or reduced by propranolol. After a control measurement, propranolol was administered intravenously until heart rates fell by at least 25%. This was usually accomplished by doses of 0.75-1.5 mg/kg. Conversely, the inotropic state of the myocardium was enhanced by i.v. infusion of isoproterenol (50 mg dissolved in 50 ml of normal saline). The rate of isoproterenol infusion was titrated until heart rate and pulsepressure amplitude increased and then maintained throughout the 20-minute recording period. To examine the relationship between flow and E of N-13 ammonia at different inotropic states, flow was increased by additional intracoronary infusion of papaverine.
Effects of Plasma pH
Arterial plasma pH was altered in five dogs. Plasma pH was decreased to values as low as 7.03 by ventilating the animals with 10% CO2 and 90% 02. Hyperventilation increased plasma pH only moderately, and sodium bicarbonate was therefore infused in two dogs until plasma pH exceeded 7.5. Arterial plasma pH, Po2 and Pco2 were frequently monitored during the experiments and always determined at the time of N-13 ammonia administration.
Effects of Arterial Plasma Glucose Concentration and Myocardial Glucose Uptake
Changes in arterial plasma glucose levels and myocardial glucose uptake were induced by fasting the dogs for 48 hours before the study. After two measurements of E for N-13 ammonia, 20% dextrose in water together with insulin (1.5-3.0 U/g glucose) was infused i.v. at a rate of 0.5 ml/min. Twenty minutes after the start of glucose and insulin infusion, a third and, 1 hour later, a fourth measurement was taken. In one dog, insulin only was administered i.v. 30 minutes before each measurement (40 U/kg).
Arterial blood gases and glucose levels were measured at the beginning and toward the end of each 20-minute experimental run. To determine the myocardial glucose uptake, the coronary sinus was cannulated and glucose levels in venous cardiac blood were obtained.
Effects of L-methionine Sulfoximine
To clarify the role of the glutamic acid-glutamine pathway for the metabolic trapping of N-13 ammonia, the mediating enzyme glutamine synthetase was inhibited in two dogs by i.v. L-methionine sulfoximine (MSO) (50-100 mg/kg; Aldrich Chemical Company).
The myocardial clearance curve of a pure intravascular tracer was determined to delineate the vascular phase of the time-activity curves and to determine the size of the vascular compartment as well as the contribution of recirculating activity to the primary timeactivity curve. Autologous red blood cells labeled with 0-15 carbon monoxide and suspended in 0.2 ml of plasma were injected into the left circumflex coronary artery in one dog. The positron emitter 0-15 was chosen to maintain the same counting conditions as during the N-13 ammonia experiments.
Measurement of Myocardial Blood Flow
Mean myocardial blood flow in the distribution of the left circumflex coronary artery was determined with calibrated electromagnetic flow probes. The calibration was performed in the following manner: Myocardial blood flow was determined at least twice by left atrial injection of carbonized microspheres (9 ± l,u in diameter and labeled with 1-125, Ce-141 or Nb-95; 3M Company) and by arterial reference 1261 VOL 63, No 6, JUNE 1981 sampling.2' Myocardial blood flow (MBF) was calculated by the equation MBF (ml/min/100 g) = (Fa X Cm X 100)/Cb (1) where F, = withdrawal rate of arterial blood (ml/ min), Cm = activity in the myocardial tissue sample (counts/min/g) and Cb = activity in the arterial reference sample (counts/min). The calculated values were then related to the flow probe output and units deflection expressed in ml/min/100 g. The two calibration measurements were performed at different myocardial blood flows. The values obtained in this manner, e.g., during papaverine-induced hyperemia, represent therefore the mean myocardial blood flow in the distribution of the left circumflex coronary artery.
The possibility that intracoronary papaverine infusion caused an increase in the actual mass of myocardium perfused by the circumflex coronary artery was examined by comparing E measured during hyperemia induced by intracoronary papaverine and i.v. dipyridamole. If papaverine increased the mass of perfused myocardium, the resulting values for E should have been higher. However, this was not the case and E under both conditions was the same. Because dipyridamole tended to produce hypotension, we preferred papaverine.
Preparation of N-13 Ammonia and 0-15 Carbon Monoxide N-13 ammonia was produced in the cyclotron by bombarding water with 21-MeV protons producing the '60(p,a)'3N nuclear reaction, followed by reduction of the 9 13 compounds to ammonia with Devarda's alloy. 22 The radiochemical purity of the product was greater than 99% N-13 ammonia and the injected aqueous solution (0.9% NaCl) contained less than 10-4M carrier ammonia as determined by liquid and gas chromatography.
The 0-15 was prepared by irradiation of nitrogen gas containing 0.95% oxygen carrier with 6-MeV deuterons producing the '4N(d,n)'50 nuclear reaction. The target gas was then passed through a bed of activated charcoal at 900°C23 for conversion to C'50, which was bubbled for 1 minute through 3 ml of the desaturated, heparinized blood. The radioactive carbon monoxide rapidly attached to hemoglobin to form carboxyhemoglobin and provided labeled red blood cells.
Statistical Analysis
Compartmental analysis of the recorded myocardial time-activity curves was performed using leastsquare curve-fitting techniques. Similarly, for statistical analysis of the relationships between E of N-13 ammonia and myocardial N-13 half-times and myocardial blood flow, least-square-fitting techniques using the magnified diagonal method24 implemented in a PDP-1 1/55 computer were used. When appropriate, the t test for paired and unpaired data was applied.
Results
A typical myocardial time-activity curve recorded after intracoronary injection of N-13 ammonia in a 0.2-ml bolus corrected for physical decay is shown in figure 1 . There was no definite vascular phase on the time-activity curves. The transit time of the coronary vascular bed is about 2 seconds. N-13 ammonia not extracted during the initial capillary transit should rapidly leave the myocardium and be reflected on the time-activity curve by an early rapid fall of activity, with a half-time of not more than several seconds. Such a vascular phase was clearly observed after intracoronary injection of 0-15-labeled red blood cells ( fig.  2 ). The vascular half-time in these four experiments averaged 3.1 ± 0.6 seconds. The demonstration of a vascular phase in these experiments indicates that its absence on the N-13 ammonia time-activity curves is not artifactual and suggests an initial extraction of N-13 ammonia during the first capillary transit that approaches 100%. 13NH3 FIGURE 2. Comparison between timeactivity curves obtained after intracoronary (i.c.) administration of 0-15-labeled red blood cells (C"0 RBCs) (left) and N-13 ammonia (right). Note the vascular phase indicated by the rapid initialfall in activity on the curve obtained with labeled red blood cells which is not seen on the N-13 ammonia curve. Further, the labeled red blood cells recirculate via the coronary sinus, right ventricle and lungs back into the left ventricle and give rise to the recirculation peak. 6 20 The ratio of the recirculation of the intravascular tracer to the initial injection peak averaged 0.51 ± 0.08 in the four experiments. The minimum recirculation time (i.e., the time from the injection peak to the onset of the recirculation curve in figure 2) was 6.6 i 1.1 seconds. These values are, of course, not strictly applicable to the N-13 ammonia time-activity curves, in which release of indicator from myocardium occurs slowly in an exponential, rather than bolus, form. They do indicate that indicator recirculation occurs rapidly and can contaminate the primary time-activity curve.
The relationship between myocardial blood flow and E and tissue clearance half-times of N-13 ammonia were studied in 64 experiments in 29 dogs. Control heart rates in these dogs averaged 149 i 19 beats/min (± SD) and mean arterial pressures 113 ± 20 mm Hg, while control flows were 103 ± 28 ml/min/100 g. The inverse relationship between both E and myocardial tissue clearance half-times of N-13 ammonia and myocardial blood flow over the range from 65-636 ml/min/100 g is shown in figures 3 and 4. The relationship between E and myocardial blood flow (F) was described by the equation 
Thus, while E averaged 0.82 ± 0.06 at control flows, it fell to 0.60 ± 0.06 at flows of 300 ml/min/100 g. Similarly, clearance half-times averaged 273 minutes at control flows and were only 152 minutes at flows of 300 ml/min/100 g. The E of N-13 ammonia in the low flow range was examined in nine experiments in six dogs. Left circumflex coronary blood flow was reduced to ischemic levels by coronary constriction for 3-5 minutes before and after intracoronary N-13 ammonia injection. The E in these experiments was lower than that predicted by the curve fit of the control and hyperemic data.
Although E should approach 100% at low flows, it actually decreased in proportion to flow ( fig. 5 ). extracted during the first capillary transit. This, then, represents the true initial extraction fraction (E') of N-13 ammonia from the vascular to the extravascular space. E' is nearly 100%, whereas E derived from the slow monoexponential phase C reflects that fraction retained in myocardium, the "retention fraction" E. The model originally proposed by Renkin25 and Crone28 to describe the E of an indicator across the capillary wall in relation to flow (F) was applied to the E' data and the following curve fit obtained: , however, approached 100% of the total injected activity (peak A) and represents the total fraction of N-13 ammonia
The data fit is similar to the Renkin/Crone equation in which E = 1.0 -e -PS/F and PS is the product of capillary permeability (P) and capillary surface area (S). Fitting the data in our study required introduction of the constant 0.096.
Effects of Inotropic Interventions and Cardiac Work
The effect of i.v. isoproterenol on E and half-time of N-13 ammonia was examined in 13 experiments in nine dogs. Isoproterenol significantly raised heart rates, from 145.3 ± 17.6 to 175.5 ± 3.0 beats/min (p < 0.001), but had no significant effect on E ( fig. 8 ) and myocardial clearance half-times. Conversely, propranolol in six experiments in four dogs produced a significant fall in heart rate and mean arterial pressures (from 164 ± 15 to 133 ± 7 beats/min, p < 0.01; and from 119 ± 16 to 104 ± 8 mm Hg, p < 0.01), while E of N-13 ammonia was unaffected ( fig. 8 ). Myocardial clearance half-times of N-13 ammonia during propranolol also did not differ significantly from control.
To examine a possible effect of cardiac work on E of N-13 ammonia, the heart rate-blood pressure product (HR X BP) was determined for studies performed at comparable flows (e.g., from 90-150 ml/min/100 g) and grouped according to HR X BP. In group 1, HR X BP averaged 16,415 mm Hg X beats/min (range 12,000-18,800), and in group 2, 22,081 mm Hg X beats/min (range 19,400-25,400 mm Hg X beats/min) (p < 0.001); however, neither E nor halftimes differed between the two groups (0.80 + 0.05 vs 0.81 ± 0.04, NS; and 306 ± 112 minutes vs 249 ± 53 minutes, NS). Using the rate-pressure product as an index of cardiac work, these data suggest that over the range studied, E and clearance half-times for N-13 ammonia were independent of cardiac work.
Effects of Plasma pH
Plasma pH was altered during 13 experiments in five dogs. At control, arterial plasma pH averaged 7.39 (range 7.37-7.44). Ventilating the dogs with 5% CO2 and 95% 02 (two experiments) and with 10% CO2 and 90% 02 (five experiments) for 20 minutes before and throughout the experimental runs reduced the plasma pH levels to as low as 7.03. Mean heart rates and systemic arterial blood pressures did not differ significantly from control, although early during 10% CO2 inhalation, heart rates tended to decrease while blood pressure and myocardial blood flow increased.
In the experiments performed with 10% CO2, E was significantly reduced for a given flow rate ( fig. 9 ). Compared with the curve fit of the control data, E at low plasma pH was reduced by an average of 19.7% fig. 9 ) nor myocardial clearance half-times.
Effects of Myocardial Glucose Uptake
Arterial glucose levels and myocardial glucose uptake were altered in 19 experimental runs in five dogs. Arterial glucose levels ranged from 38-868 mg/ 100 ml and myocardial glucose uptake from 0.61-51.5 mg/min/ 100 g. However, there is no definite relationship between E and arterial plasma glucose levels or myocardial glucose uptake ( fig. 10 ).
Effect of L-methionine Sulfoximine
Intravenous MSO in seven experiments in two dogs had no effect on heart rate or systemic arterial blood pressure, but considerably altered E and the retention of N-13 ammonia in myocardium. The time-activity curves no longer showed the early decrease in activity, followed by the monoexponential residue function, but a continuous multiexponential decline in activity ( fig.  1 1) . Curve-stripping techniques identified three main components. From the slow phase, a mean E of N-13 ammonia of 0.16 ± 0.04 (SD) was calculated and was significantly lower than E at control (0.68 ± 0.06) at comparable blood flows of 200 ml/min/100 g.
Moreover, the clearance half-times of the initial fast component ranged from 24.4-45.7 seconds. They were thus in the range of those observed for the phase B during the control studies and were also inversely related to myocardial blood flow (half-time = 52.1 -0.09F) (r = 0.70; fig. 6 ).
Discussion
This study was designed to examine factors that may alter the uptake and retention of N-13 ammonia in myocardium and to characterize the kinetics of this agent with respect to its suitability as a myocardial perfusion imaging agent. The intracoronary administration of N-13 ammonia as the experimental approach in this study was preferred to techniques that use systemic tracer administration because it avoids the complexities of tracer recirculation, allows direct inspection and measurement of the forward and reverse transport and metabolic trapping during selected interventions. The approach has been used and extensively validated.`5~`7 The results indicate that both uptake and retention of N-13 ammonia in myocardium are primarily related to myocardial blood flow and the rate of metabolic trapping. 
Myocardial Blood Flow and N-13 Ammonia Uptake and Retention
The myocardial time-activity curves recorded after intracoronary injection of N-13 ammonia did not show a clearly identifiable vascular phase. In this regard, they distinctly differed from those in the brain, where the slow monoexponential residue function is preceded by a fast vascular component, with a mean transit-time of 2-4 seconds. 5 The possibility that the Myocardial bloodflow (MBF) was 295 ml/min/100 g. Note the absence of the typical biphasic appearance. N-13 ammonia clears from myocardium in a multiexponential fashion and only 16% is retained.
phase in these studies, 3.1 ± 0.6 (SD), is considerably shorter than the half-times of the intermediate phase B on the N-13 ammonia time-activity curves, ranging from 11-52 seconds. Interestingly, these clearance half-times of N-13 ammonia are comparable to those reported for diffusible flow indicators. For example, at flows of 100 ml/min/100 g, the myocardial half-time of radioactive water (H2150) is about 38 seconds"' and for xenon-133, about 28 seconds,28 while that of N-13 ammonia was 34 seconds. The myocardial clearance halftimes of a freely diffusible indicator reflect the volume of distribution of the tracer, partition coefficient of the tracer and blood flow as described by the Kety-Schmidt formula.29 Therefore, if N-13 ammonia diffuses back into the vascular space during phase B, the clearance half-time should be related to flow. The data shown in figure 6 suggest such a relationship. The considerable scatter of the data, especially in the lowflow range, may be a result of several factors. The clearance half-time of N-13 ammonia during phase B is not a function of flow alone, but may also be related to weak binding to tissue constituents. Recirculation of activity into the detector field of view may contaminate the primary time-activity curve,"' as evidenced by the studies with 0-15-labeled red blood cells, with recirculation occurring within 6 seconds. The ratio of heights of the recirculation to the initial injection peak was 0.50 for the vascular tracer studies. The magnitude of contribution of activity from recirculation to the primary curve is considerably less for N-13 ammonia, because a major fraction is initially retained in myocardium and the subsequent release of untrapped N-13 ammonia is exponential and rapidly extracted by other organs.1 At low flows, phase B is quite small, and curve stripping for calculation of the half-times is subject to considerable error. Inhibition of metabolic trapping of N-13 ammonia by MSO considerably increased the size of the back-diffusion component. The clearance half-times under this condition correlated better with blood flow ( fig. 6 ), although they were above or in the high range of the control data. The prolongation of the apparent clearance of N-13 ammonia from myocardium is caused by recirculating activity, which in the study by Metzger'9 increased the clearance half-times by an average of 25%. The size of the intermediate component (expressed as the fraction of the total activity injected) was also a function of blood flow. That is, as flow increased, more N-13 ammonia diffused back into the vascular space so that less became available for fixation in myocardium. Nevertheless, at control flows of 100 ml/min/100 g, the sum of the slow and the intermediate components approached 100% of the total injected activity and declined only slightly at high flows, where a small vascular component was noted on the time-activity curves. This suggests an almost complete extraction of N-13 ammonia during the initial capillary transit. Together with absence of a significant vascular phase on the time-activity curve, it implies that the capillary wall does not exert a significant barrier effect on the exchange of N-13 ammonia between intra-and extravascular space.
In blood, ammonia is in equilibrium with ionic NH4+, ammonium, which at physiologic pH represents more than 95% of the total ammonia.30 If only the ionic species left the vascular compartment, E of N-13 ammonia in myocardium probably would be comparable to that of K+. Using a similar experimental approach, Poe'8 observed a mean E of 71% for K+, which is considerably lower than that for N-13 ammonia in our study.
Applying the Renkin-Crone model to the initial extraction fraction, designated here E', the best data fit of our data for the relation between E and F was achieved with the equation 3. The equation can be rearranged to
The term (103 + 2.3F) is the PS product and indicates that the original Renkin-Crone model is not strictly in agreement with our data and that the PS area product is not constant but a function of flow. The flow dependency of the PS product in myocardium is consistent with that in the brain recently reported by Phelps et al.,27 who explained these data in terms of a "saturable recruitment model." This model takes into account changes in the PS product related to blood flow and attributes an increase in capillary blood flow to capillary recruitment and an increase in blood velocity through open capillaries. From equation 4, the P for N-13 ammonia can be calculated. Assuming for S 500 cm2/g myocardium,31' 32 it predicts a P of 5.6 X 10-2 cm X sec`at a flow of 100 ml/min/100 g. This value is of the same order of magnitude as the P of 1.08 X 10-2 cm X sec-' reported by Klocke et al.4 for the permeability of ammonia across red blood cell membranes. Although exchange across cell membranes and the capillary wall are not strictly comparable, the similarity of the two values nevertheless suggests diffusion of nonionized ammonia across the capillary wall. As N-13 ammonia leaves the vascular space it must be rapidly replenished by conversion of NH4+ to NH3. This requires about 19 ,sec to achieve equilibrium5 and is fast enough to permit almost complete extraction of N-13 ammonia during the 2-3 second transit through the myocardial capillaries. If, as it appears from these observations, the capillary wall does not exert a significant barrier effect, the rate-limiting step for the uptake of N-13 ammonia must be either at the level of the sarcolemma or the rate of metabolic trapping.
Metabolic Fixation of N-13 Ammonia in Myocardium
The presence of glutamine synthetase, and hence, of the glutamic acid-glutamine reaction in mammalian myocardium, has been questioned.3 In our experiments, however, the glutamine synthetase inhibitor MS034 profoundly affected the myocardial uptake and kinetics of N-13 ammonia. For example, the E for N-13 ammonia in myocardium fell to 16 ± 4%, compared with a mean of 68% at control at similar blood flows (200 ml/min/100 g). These observations not only emphasize the importance of metabolism for the trapping of N-13 ammonia in myocardium and, further, for its use as a myocardial blood flow imaging agent, but are also in agreement with more recent reports strongly suggesting the existence of the glutamic acid-glutamine pathway in myocardium., 6, 9, 10, 3 Although MSO is not an entirely specific inhibitor of glutamine synthetase,38 its effect on myocardial N-13 ammonia uptake supports the hypothesis that amidation of glutamic acid with ammonia to glutamine is the principal route for removal or fixation of exogenous ammonia in myocardium. 5 10 In earlier studies in the isolated perfused heart and in dogs, the nitrogen atom of exogenous N-15 ammonia appeared primarily in tissue glutamine of cardiac and skeletal muscle6' 9 and, more specifically, in the amide group of glutamine.37
From our own observations and those of others, one can assume that the slow, monoexponential residue function of the time-activity curve reflects N-13 activity that has been incorporated primarily into glutamine. In our study, the residual function or fraction of N-13 ammonia that became metabolically trapped during a single capillary transit was inversely related to myocardial blood flow, as described by equation 2. Thus, for a resting myocardial blood flow of 80 ml/min/100 g, E for N-13 ammonia averages 0.87 ± 0.06 but only 0.58 at flows of 350 ml/min/ 100 g as they occur in man during exercise. 38, 39 The inverse relationship between E and F may also account for the observations in the isolated perfused rabbit heart recently reported by Bergmann et al. 35 In these 1267 VOL 63, No 6, JUNE 1981 hearts, E for N-13 ammonia averaged 0.18 when perfused with Krebs-Heneleit buffer (KH), but was 0.55 when red blood cells were added to the perfusion medium (KH-RBC). The authors concluded that this difference in E was related to changes in metabolism of the isolated heart. Adequate oxygenation of the heart required perfusion rates of 140 ml/min/100 g KH-RBC and of 420 ml/min/100 g during perfusion with KH. For such a flow increase, equation 2 predicts an absolute fall in E of 0.2, while that reported in the rabbit hearts was 0.37. The decrease therefore may be primarily related to flow rather than to metabolic trapping of N-13 ammonia.
As opposed to E', E defines the fraction of N-13 ammonia that becomes metabolically fixed in myocardium and represents the N-13 activity visualized by external imaging techniques. The half-time of this phase ranged from 87.5-386 minutes and was inversely related to blood flow. The mechanism of glutamine release from myocardium is uncertain. Although the glutamine synthetase reaction is reversible and glutamine could be catalyzed to glutamic acid and ammonia, the equilibrium of the reaction lies distinctly in the direction of synthesis. 40 Moreover, glutamine appears to cross the cell membrane more readily than glutamate. 40 Although the turnover rate of glutamine in myocardium has not been determined, the data obtained by Ruderman and Lund41 in the isolated perfused hind limb of the rat predict a halftime of glutamine in skeletal muscle of 129 minutes, a value comparable to our findings in the dog heart.
Kinetics of N-13 Ammonia in Myocardium
From our experimental results, we propose the following model for the exchange and uptake of N-13 ammonia in myocardium ( fig. 12 ): N-13 ammonia freely crosses the capillary wall and is nearly 100% extracted during its initial capillary transit. While the possibility of a barrier effect on the exchange across the cell membrane itself cannot be excluded from our data, it seems unlikely, in view of the observation of Klocke et al.4 on red blood cell membranes. Thus, the rate of metabolic fixation appears to be the rate-limiting step. For example, N-13 ammonia distributes in the extravascular space and back diffusion competes with metabolic trapping. If the rate of metabolic trapping of N-13 ammonia can be assumed to be constant, the fraction of N-13 ammonia ultimately bound in myocardium is related to the rate of back diffusion and thereby to blood flow. Hence, at higher flows, more N-13 ammonia diffuses back into the intravascular compartment and the fraction of N-13 ammonia retained in myocardium declines.
Although a number of metabolic routes are available to the cell for N-13 ammonia fixation, the glutamic acid-glutamine and, to a lesser degree, the ketoglutarate-glutamic acid reactions appear to be the primary trapping mechanisms. Duda and Handler's work42 and the effects of glutamine synthetase inhibition by MSO in our study further support the hypothesis that amidation of glutamic acid with ammonia to glutamine represents in fact the main route for metabolic trapping and fixation of N-13 ammonia in myocardium. Glutamine is then slowly released from the cell and serves as a carrier of ammonia for excretion.
Metabolic Trapping of N-13 Ammonia
The proposed model emphasizes the importance of metabolic trapping. If its rate were highly susceptible to changes in cardiac metabolism, it would seriously limit the value of N-13 ammonia as a flow indicator. Mechanisms that could interfere with metabolic trapping of N-13 ammonia are competition with endogenous ammonia for substrates or saturation of the glutamate-glutamine pathway; depletion of substrates required for binding, i.e., glutamic acid; and changes in the enzyme activity regulating the rate of metabolic fixation. Intracellular concentrations of ammonia can increase with high cardiac work or during isoproterenol infusion..6 ' 11, 12 However, the increase does not appear large enough to saturate the trapping mechanism, because E and retention of N-13 ammonia in myocardium did not differ at various levels of cardiac work, nor were they affected by changes in the myocardial inotropic state. In addition to 3-blockade, the high doses of propranolol used in these dogs may also have caused cardiac depression,43 which, however, did not affect the trapping of N-13 ammonia. The linear relationship between myocardial extraction and arterial concentrations of ammonia observed in dogs" is further support for the large capacity of the intracellular removal mechanism for ammonia. Nevertheless, saturation of the glutamate-glutamine pathway is possible. Perfusion of the isolated rat heart with 2.6 mM concentrations of ammonia over 30 minutes caused a rise in intracellular glutamine and ammonia concentrations and a greater release of ammonia from the cell, but did not occur with 0.7 mM ammonia concentrations in the perfusate.7 In our experiments, far less ammonia was presented to the heart (< 10-5 mM per 0.2-ml bolus). In the isolated heart, amino acid precursors for glutamine synthesis could have been depleted and reduced the capacity of the cell for ammonia fixation. This could account for the lower E of N-13 ammonia reported by Bergmann et al. 35 in the isolated rabbit heart. It would be consistent with the progressive decline of glutamine synthesis in skeletal muscle during prolonged incubation, which can be prevented by addition of amino acids to the incubation medium. 4 If the glutamic acid-glutamine pathway is the primary route for ammonia fixation, the rate of N-13 ammonia trapping could be limited by the availability of glutamic acid. However, under physiologic conditions the glutamic acid pool appears to be quite large and can be rapidly replenished by exogenous a-ketoglutarate and glutamate,40 by protein degradation,41' 44 deamination of AMP, or through a-ketoglutarate via formation from oxaloacetic acid or directly from the citric acid cycle. Through pyruvate, oxaloacetic acid, and a-ketoglutarate, the amino acid metabolism is linked to glycolysis and the citric acid cycle. Despite these relationships, alterations in the rate of glucose utilization, arterial plasma glucose levels, insulin administration, or prolonged fasting did not interfere with the metabolic fixation of N-13 ammonia.
extravasc. compartment
Low plasma pH and transient ischemia were the only interventions that decreased the E of N-13 ammonia, although neither significantly altered the myocardial clearance half-times of N-13 activity. Because the time-activity curves remained without a distinct vascular phase during these interventions, it is unlikely that they impaired the exchange of N-13 ammonia across the capillary wall. The fall in E therefore could be due to alterations either in the N-13 ammonia transport across the cell membrane or the rate of metabolic trapping. In the brain, changes in the transmembranous pH gradient are known to alter the the NHS/NH,+ ratios in the intraand extracellular spaces. 45 46 While this applies to steady-state distributions, it is not possible to determine from our data whether the low plasma pH depressed the rate of conversion of NH4+ to NH3 in the extracellular space so that less ammonia was available for diffusion across the sarcolemmal membranes. This mechanism, however, seems unlikely because elevations of the plasma pH did not raise E of N-13 ammonia in myocardium.
Acidosis was induced by ventilation with 5-10% CO2 and 95 or 90% 02, which considerably raised the arterial Pco2 (average 79.4 mm Hg). This is associated with a fall in myocardial and probably intracellular pH. 47 In the liver and kidney, the activity of glutamine synthetase activity can be altered by perfusate or tissue pH.48 50 No data are available on the pH dependency of glutamine synthetase activity in myocardium, although in the isolated perfused rat hind quarter, reduction of the perfusate pH by lowering bicarbonate concentrations increased glutamine synthesis activity in skeletal muscle.49 This is difficult to reconcile with our own observations of a decrease in E for N-13 ammonia during low plasma pH levels unless, as postulated by Oliver et al.,49 waste nitrogen no longer is incorporated into urea, but into glutamine, leading to a depletion of glutamate as the substrate for binding of either endogenous or exogenous ammonia. However, the experimental conditions are not strictly comparable because bicarbonate levels in our experiments were elevated rather than decreased, as in the study by Oliver et al.
The lower E of N-13 ammonia observed in our experiments during ischemia may similarly have been related to a fall in myocardial pH.5" Amidation of glutamic acid with ammonia to glutamine requires energy, so reduction of ATP levels during ischemia also could have interfered with metabolic fixation of N-13 ammonia. Finally, increased ammonia production during ischemia6' 7, 12 and an augmented conversion of glutamate to succinate, as recently observed during anoxia in the rabbit heart,52 53 may have caused a depletion of substrates required for ammonia fixation.
Comparison of N-13 Ammonia Kinetics in Brain and Heart
While the findings in the current study suggest a number of similarities for the uptake and retention of N-13 ammonia in brain and myocardium, in several aspects they differ distinctly. Metabolic trapping of N-13 ammonia in myocardium occurs primarily via the glutamate-glutamine pathway, as has been demonstrated for the fixation of N-13 ammonia in the brain.9 10 Moreover, E of N-13 ammonia is inversely related to blood flow in both myocardium and brain as demonstrated by Phelps et al. 5 27 In both organs, the experimental data did not agree strictly with the Renkin/Crone model and suggested a flow dependency of the PS product. In contrast to the brain, where the capillary membrane apparently represents the rate-limiting step for the extraction of N-13 ammonia, the capillary wall in myocardium does not appear to 1269 distribution of ammonia mainly because of shifts in VOL 63, No 6, JUNE 1981 exert a significant barrier effect. This difference probably results from the tight junctions of the bloodbrain barrier as opposed to the fenestrations of the myocardial capillaries, where the high water solubility of N-13 ammonia may account for the higher extraction. As mentioned earlier, N-13 ammonia during its initial capillary transit through the heart was nearly 100% extracted at control flows and accounted for the absence of a vascular phase on the time-activity curves that was clearly apparent on those obtained in the brain.' With respect to its value as a blood flow imaging agent, N-13 ammonia appears better in the heart than in the brain. In both organs, the net extraction or tissue concentrations of N-13 ammonia are almost linearly related to perfusion within the low flow range. However, in the hyperemic range, the response of N-13 ammonia tissue concentrations to flow plateaus at flows more than two times the control in the brain. while in myocardium this occurs at flows more than four times control' and is probably due to its greater capillary flow reserve.
N-13 Ammonia as Myocardial Blood Flow Imaging Agent
Myocardial N-13 tissue concentrations are a function of the amount of N-13 ammonia presented to the tissue, its extraction fraction and blood flow. Accordingly, the net extraction of N-13 ammonia or the tissue N-13 concentrations can be predicted from the product of F times E (or the amount of N-13 ammonia delivered to times the fraction extracted and retained in tissue, which corresponds to the slow phase C on the time-activity curves). This is shown in figure 13 from the E and F data collected in this study, and clearly demonstrates how the N-13 tissue concentrations increase in proportion to myocardial blood flow. The curve describing the relationship between flow and myocardial tissue concentrations of N-13 ammonia is similar to that determined by in vitro tissue counting techniques' and predicts a relatively linear response of N-13 tissue concentrations to blood flow within the physiologic range, e.g., for flows from near zero to as high as 350 ml/min/100 g, as may occur in man during maximum exercise.38' 39 Thus, a 100% rise in flow above control is associated with a 70% increase in N-13 ammonia tissue concentration.
Next to blood flow, metabolic trapping plays a major role in the uptake and fixation of N-13 ammonia in myocardium. The dependency of E of N-13 ammonia on myocardial metabolism has recently been emphasized by Bergmann et al. 35 These investigators observed in isolated perfused rabbit hearts a considerable fall in E of N-13 ammonia when the perfusion medium did not contain red blood cells and concluded that different perfusion media were associated with changes in the metabolic state which conversely affected the metabolic trapping of N-13 ammonia. As mentioned earlier, the decrease in E of N-13 ammonia in these isolated hearts could have been due to the higher perfusion rates rather than, as concluded by the authors, to changes in metabolism. Moreover, E varied considerably between individual measure-ments in the rabbit hearts. Shunting of blood or, more likely, varying degrees of depletion of the amino acid precursor pools during perfusion of isolated hearts,"3 may have caused this. The significantly faster tissue N-13 clearance rates in the isolated hearts would be consistent with a more rapid loss of myocardial amino acids. While the metabolic intactness of the isolated hearts was based also on their mechanical performance, this index may be independent of amino acid metabolism. For example, in both the isolated heart and the open-chest dog, inhibition of the glutamine synthetase activity by MSO had no effect on cardiac performance.
Bergmann and associates35 studied the myocardial accumulation of N-13 ammonia only over the range of ischemic to basal flows. Contrary to our findings, hypoperfusion of the isolated hearts did not reduce E of N-13 ammonia. The product of E times F or the net extraction of N-13 ammonia therefore would predict a linear response of tissue N-13 ammonia concentrations to flow, which is consistent with the relationship between tissue N-13 ammonia concentrations and blood flow in the ischemic range reported by Walsh et al.'4 and in our study.
Our results indicate that the trapping mechanism is relatively stable over a wide range of changes in the metabolic and functional state of the heart, which therefore do not significantly affect the response in N-13 tissue concentrations to flow. Only markedly reduced plasma pH levels and ischemia affected the metabolic fixation. Plasma pH levels as low as in these experiments are unlikely to occur in patients and therefore would not seriously limit the tissue concentrations and flow. Because the decrease in E occurred in proportion to flow, the relationship between flow and tissue N-13 concentrations can be corrected for appropriately in the low flow range as shown by the comparison' between the predicted and measured values in figure 13 . The considerable scatter of the data points ( fig. 13 ) is probably related to methodologic errors in measuring E and inaccuracies in determining very high flows with the microsphere technique. Although the overall predicted response is similar to that reported earlier,' the accuracy and certainty with which regional flow can be predicted would be assessed more adequately from direct tissue counting. In fact, the relationship determined in this manner in our previous study shows considerably less variability than the calculated data in our present study. Further, the hemodynamic state in these open-chest dogs differs from that in conscious animals or in man. Heart rates and myocardial blood flow were approximately twice as high as in man at rest. Thus, direct application of these experimental findings should be made with cautio'n, although a number of control measurements were performed at flows and heart rates similar to those in resting man.
The myocardial clearance half-times of N-13 ammonia are related to flow and may to some'extent alter the distribution of this indicator over' time. Yet the degree of "redistribution" from injection to imaging, e.g., within 15 minutes (imaging with positron emission tomography is usually from 2-20 minutes after injection), is very small and would result in a 3% change in the ratio of concentration between high control flow's and a 1% change of the ratio between control and ischemic flows.
The relatively long myocardial half-times offer a distinct advantage for the practical use of N-13 ammonia as a myocardial perfusion imaging agent. As N-13 ammonia concentrates in myocardium in proportion to blood flow, this distributi'on is maintained so that at the time of imaging the regional myocardial N-13 tissue concentrations closely reflect the regional distribution of blood flows at the time of injection. In this respect, N-13 ammonia appears better than thallium-201, which can rapidly redistribute66 so that only scintigrams obtained early after administration do indeed reflect myocardial blood flow.
